Following a full submission
fluticasone furoate (Avamys) is accepted for use within NHS Scotland for the treatment of the symptoms of allergic rhinitis in adults, adolescents (12 years and over) and children (6 to 11 years).
Evidence to support its efficacy comes from a number of comparator- and placebo-controlled studies conducted in adults and children with seasonal and perennial allergic rhinitis.
Prescribers should be aware that the recommended doses of fluticasone furoate are not equivalent, on a microgram per microgram basis, to other fluticasone nasal sprays currently available.
Other intranasal steroids are available at a lower cost
Download detailed advice84KB (PDF)
- Medicine name:
- fluticasone furoate (Avamys)
- SMC ID:
- Allergic rhinitis in adults adolescents (12 years+) and children (6 to 11 years)
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Ear, nose and oropharynx
- Submission type
- Date advice published
- 14 April 2009